Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BDTX · NASDAQ · Biological Products, (No Diagnostic Substances)
$1.31−0.08 (−5.76%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Black Diamond Therapeutics (BDTX) · oqro.io/stocks/BDTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Fund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 14, 2025
Bellevue Group AG disclosed a reduced position in BDTX for Q1 2025SourceInsider trade · Traded Mar 19, 2025 · Filed Mar 21, 2025
10% owner sold ~$4M of BDTX shares in the open marketSourceInsider trade · Traded Mar 19, 2025 · Filed Mar 21, 2025
10% owner sold ~$2.31M of BDTX shares in the open marketSourceInsider trade · Traded Mar 19, 2025 · Filed Mar 21, 2025
10% owner sold ~$2.07M of BDTX shares in the open marketSourceInsider trade · Traded Mar 19, 2025 · Filed Mar 21, 2025
10% owner sold ~$1.14M of BDTX shares in the open marketSourceInsider trade · Traded Mar 19, 2025 · Filed Mar 21, 2025
10% owner sold ~$1.06M of BDTX shares in the open marketSourceInsider trade · Traded Mar 19, 2025 · Filed Mar 21, 2025
10% owner sold ~$837K of BDTX shares in the open marketSourceInsider trade · Traded Mar 19, 2025 · Filed Mar 21, 2025
10% owner sold ~$583K of BDTX shares in the open marketSource